The huge funding gap for European biotech is structural. European institutional investors like pension funds allocate only 0.02% of their balance sheets to venture, compared to 2% in the US. This factor-of-100 difference creates a major hurdle for the ecosystem's ability to retain its champion companies.

Even as the biotech financing environment improves, investors maintain high standards. The challenge isn't finding investors but building enough conviction to make them invest. Capital is available, but not easily accessible to all.

Europe generates scientific output and IP comparable to the US but fails to translate it into successful companies at the same rate. Key challenges include a lack of deep capital markets, a lower cultural risk appetite, and a smaller talent pool, pushing many promising European biotechs to seek funding and IPOs in the US.

Veteran VC Edward Van Wezel notes a dramatic shift in biotech financing. Seed rounds that were once a few million and Series A rounds around €15-20M have both increased by nearly a factor of five. This inflation has reshaped the investor landscape and the capital strategy required to build a successful biotech company.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

Despite discussions of European self-reliance, its capital markets remain inadequate for scaling biotech companies. Over the past 10 years, only three biotechs managed to raise over €100 million in an IPO on a European exchange, compared to 27 European biotechs that achieved this on NASDAQ in the same period.

A profound capital shift has occurred where both venture investors and large pharma partners focus on clinically validated assets. This moves investment away from riskier, early-stage science, creating a significant funding gap for foundational research and pre-clinical startups.

A wave of M&A for late-stage biotech companies is a leading indicator of improved funding for early-stage ventures. Successful exits draw more capital back into the sector from both specialist and generalist investors. This cash infusion typically flows down to seed and Series A rounds after a 6-12 month lag.

To remain globally competitive against the US and China, European biotech should focus on its core strength: high-quality, innovative early-stage science. The speaker suggests that while Europe excels at invention, scaling companies still requires tapping into the US market, capital, and talent, positioning Europe as a premier origination hub.